Fotona Dental Lasers in 2026: New Leadership, Smarter Systems, and a Shifting Competitive Landscape

Laser dentistry is no longer a niche offering — it is rapidly becoming the standard of care for practices that prioritize precision, patient comfort, and clinical versatility. At the forefront of this transformation stands Fotona, whose dual-wavelength technology continues to generate compelling clinical evidence while the company simultaneously expands its leadership team, launches patient-facing campaigns, and refines its flagship hardware. This week's roundup covers the latest clinical research, industry developments, competitive dynamics, and technological innovations shaping Fotona's role in modern dentistry.

Clinical Research: SWEEPS® Gains Long-Term Validation

One of the most significant areas of ongoing clinical investigation involves Fotona's SWEEPS® (Shock Wave Enhanced Emission Photoacoustic Streaming) technology for endodontic decontamination. A 2026 systematic review and meta-analysis comparing laser-activated irrigation — including SWEEPS® — against ultrasonic-activated irrigation has added to a growing body of evidence confirming the protocol's superiority in removing infected tissue and smear layers from complex root canal anatomies.

What makes SWEEPS® particularly compelling is its ability to reach lateral canals and dentinal tubules that conventional irrigation simply cannot access. By generating synchronized ultra-short Er:YAG pulses that create photoacoustic shockwaves within the irrigant, the system achieves thorough debridement without aggressive canal shaping. Critically, two-year follow-up data now available in the literature validates the long-term success of these treatments — a milestone that gives clinicians and patients alike greater confidence in the procedure's durability.

The patented R-SWEEPS® mode takes this further by increasing pressure generation along the root canal without raising the risk of apical extrusion, enabling effective — and often single-visit — treatment even in anatomically challenging cases. As Dental Tribune has noted, SWEEPS® is increasingly regarded as a "game-changer" in modern endodontics.

On the sleep medicine front, Fotona's NightLase® protocol continues to attract research attention. Using the non-ablative Er:YAG SMOOTH® mode, NightLase® stimulates collagen contraction and neo-collagenesis in the soft palate and surrounding oral tissues, tightening the airway without surgery or anesthesia. A study published in the European Archives of Oto-Rhino-Laryngology assessed its safety and clinical outcomes versus sham treatments, reinforcing its role as a viable, patient-friendly alternative for those who cannot tolerate CPAP devices or prefer to avoid surgical intervention. Results typically last up to a year, with maintenance sessions available thereafter.

Industry News: A New CPO and the FotonaSMILE Campaign

September 2026 brought a significant organizational development: Fotona appointed Alasdair Owen as its inaugural Chief Product Officer, effective August 24. Owen, who previously led European Product Portfolio Marketing at Intuitive — the company behind the da Vinci surgical robotics platform — now reports directly to CEO Jeff Duchemin. His mandate spans global product strategy, R&D, and portfolio development across aesthetics, dermatology, dentistry, women's health, and surgery. The creation of this role signals Fotona's intent to accelerate its innovation pipeline and sharpen its competitive positioning across all medical specialties.

On the patient-facing side, the FotonaSMILE campaign — launched in March 2026 — continues to gain traction. Built around the "7 Secrets of the FotonaSMILE" framework, the initiative educates practitioners on integrating a suite of minimally invasive aesthetic procedures using the LightWalker® platform. These include:

• TouchWhite® — laser-assisted teeth whitening
• LipLase® — natural lip enhancement via collagen stimulation
• Gum Depigmentation — removal of melanin-related discoloration
• SmoothLiftin™ — intraoral collagen remodeling for perioral rejuvenation
• Gingivectomy & Crown Lengthening — correction of gummy smiles
• Mucosal Lesion Treatment — Nd:YAG therapy for vascular lesions and herpes/aphthae
• Ceramic Debonding — safe removal of veneers, crowns, and brackets

A biweekly webinar series and a live expert discussion held in May have helped practices communicate these offerings to patients and position themselves in the premium aesthetic dentistry market. The company also hosted the 2026 Fotona Super Symposium in Irving, Texas (September 10–12), featuring a robust dental track covering AI-guided dynamic navigation, photobiomodulation, pediatric laser dentistry, and practice integration strategies.

Competitor Landscape: MegaGen Revitalizes BIOLASE

The competitive landscape in dental lasers shifted meaningfully in 2026 as the MegaGen–BIOLASE integration moved into full operational mode. MegaGen Implant, which acquired BIOLASE for $20 million in a court-supervised bankruptcy auction in late 2024, invested nearly $1 million in June 2026 to expand the BIOLASE manufacturing facility in Corona, California — adding cleanrooms, upgraded laser and fiber rooms, and improved warehouse capacity. From July 1, 2026, MegaGen America assumed full control of BIOLASE's US commercial operations, including sales, customer support, and training.

This revitalization matters for the broader market. BIOLASE's Waterlase system — which uses an Er,Cr:YSGG laser at 2,780 nm combined with a water spray (hydrophotonics) — had been losing ground during the company's financial difficulties. With MegaGen's manufacturing muscle and distribution network behind it, Waterlase is poised to re-emerge as a more formidable competitor to Fotona's LightWalker line.

Meanwhile, Convergent Dental's Solea — a 9.3-micron CO2 laser capable of performing approximately 95% of procedures without local anesthesia — continues to appeal to high-volume general practices prioritizing speed and patient comfort. Where Solea excels in streamlined all-tissue switching, Fotona's dual-wavelength Er:YAG + Nd:YAG architecture offers deeper clinical versatility, particularly for complex periodontal, endodontic, and aesthetic applications that benefit from wavelength-specific tissue interaction.

Innovations: LightWalker® Max and AI-Driven Dentistry

The LightWalker® Max represents Fotona's most ambitious hardware integration to date. By combining the Er:YAG and Nd:YAG wavelengths with the aesthetic protocols previously associated with the TimeWalker® and Fotona4D® Pro platforms, the Max enables dental practices to offer facial rejuvenation, hair removal, and vascular lesion treatment alongside their core clinical services — all from a single device. Key technologies include:

• VSP (Variable Square Pulse) — consistent, square-shaped energy delivery to minimize thermal buildup
• ASP (Adaptive Structured Pulse) — adaptive pulse durations for optimized tissue interaction
• MatrixView® — non-contact real-time skin temperature monitoring with color-coded safety alerts
• OPTOflex® articulated arm — distortion-free beam delivery and enhanced maneuverability

This convergence of dental and aesthetic capabilities reflects a broader market trend: the global dental laser market, valued at approximately $390–447 million in 2026, is projected to reach $676–865 million by 2033–2035 (CAGR of 7.6–9.7%), driven by demand for minimally invasive, pain-reduced procedures. AI integration is emerging as the next frontier, with systems increasingly incorporating real-time tissue analysis, predictive results modeling, and automated parameter control. Fotona's Super Symposium featured sessions on AI-guided dynamic navigation — a preview of where the technology is heading.

Conclusion

Fotona enters the final quarter of 2026 with considerable momentum: long-term clinical validation for SWEEPS®, a growing evidence base for NightLase®, a new CPO to drive product innovation, and the LightWalker® Max positioning practices to capture both dental and aesthetic revenue streams. The competitive environment is intensifying — a reinvigorated BIOLASE/MegaGen and a fast-moving Solea ensure that Fotona cannot rest on its laurels. But with its dual-wavelength versatility, robust educational ecosystem, and a clear strategic vision under new leadership, Fotona remains one of the most compelling platforms in laser dentistry today.

Sources: Fotona SWEEPS® | Dental Tribune on SWEEPS® | NightLase® Research | Fotona CPO Announcement | FotonaSMILE Campaign | MegaGen/BIOLASE Manufacturing | LightWalker® Max | Dental Laser Market